BR0016510A - Aperfeçoamentos em ou relacionados as respostas imunes ao hiv - Google Patents

Aperfeçoamentos em ou relacionados as respostas imunes ao hiv

Info

Publication number
BR0016510A
BR0016510A BR0016510-7A BR0016510A BR0016510A BR 0016510 A BR0016510 A BR 0016510A BR 0016510 A BR0016510 A BR 0016510A BR 0016510 A BR0016510 A BR 0016510A
Authority
BR
Brazil
Prior art keywords
hiv
immune responses
imonogene
clades
synthetic polypeptide
Prior art date
Application number
BR0016510-7A
Other languages
English (en)
Inventor
Thomas Hanke
Andrew James Mcmichael
Original Assignee
Medical Res Council
Int Aids Vaccine Initiative
Univ Nairobi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930294.5A external-priority patent/GB9930294D0/en
Priority claimed from GB0025234A external-priority patent/GB0025234D0/en
Application filed by Medical Res Council, Int Aids Vaccine Initiative, Univ Nairobi filed Critical Medical Res Council
Publication of BR0016510A publication Critical patent/BR0016510A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"APERFEIçOAMENTOS EM OU RELACIONADOS AS RESPOSTAS IMUNES AO HIV". Está descrito um imonogene na forma estéril adequada para administração a um paciente humano, o imonogene compreendendo: pelo menos uma porção da proteína gag de HIV, referida proteína gag sendo a partir de um clade de HIV ou possuindo seq³ência com consenso para um ou mais clades HIV, e compreendendo pelo menos partes de p17 e p24; e um polipeptídio sintético compreendendo uma pluralidade de seq³ências de amino ácidos, cada seq³ência compreendendo um epítopo CTL humano de uma proteína de HIV, e em que uma pluralidade de proteínas de HIV são representadas no polipeptídio sintético, referidos epítopos CTL sendo selecionadas para estimular uma resposta imune para um ou mais clades HIV de interesse.
BR0016510-7A 1999-12-23 2000-12-22 Aperfeçoamentos em ou relacionados as respostas imunes ao hiv BR0016510A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930294.5A GB9930294D0 (en) 1999-12-23 1999-12-23 Improvements in or relating to immune responses to HIV
GB0025234A GB0025234D0 (en) 2000-10-14 2000-10-14 Improvements in or relating to immune responses to HIV
PCT/GB2000/004984 WO2001047955A2 (en) 1999-12-23 2000-12-22 Improvements in or relating to immune responses to hiv

Publications (1)

Publication Number Publication Date
BR0016510A true BR0016510A (pt) 2002-08-27

Family

ID=26245157

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016510-7A BR0016510A (pt) 1999-12-23 2000-12-22 Aperfeçoamentos em ou relacionados as respostas imunes ao hiv

Country Status (15)

Country Link
US (1) US7993651B2 (pt)
EP (1) EP1240186B1 (pt)
JP (1) JP4805511B2 (pt)
CN (1) CN1213068C (pt)
AT (1) ATE457996T1 (pt)
AU (1) AU784679B2 (pt)
BR (1) BR0016510A (pt)
CA (1) CA2392877C (pt)
CY (1) CY1110917T1 (pt)
DE (1) DE60043856D1 (pt)
DK (1) DK1240186T3 (pt)
ES (1) ES2341429T3 (pt)
MX (1) MXPA02006379A (pt)
PT (1) PT1240186E (pt)
WO (1) WO2001047955A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US20020106798A1 (en) 2000-03-02 2002-08-08 Robinson Harriet L. DNA expression vectors and methods of use
CN100446812C (zh) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 表达修饰的hiv包膜、gag和pol基因的mva
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP4601956B2 (ja) * 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7425611B2 (en) * 2003-03-28 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Immunogenic HIV-1 multi-clade, multivalent constructs and methods of their use
CN1913919B (zh) 2003-09-15 2011-10-19 美国政府健康及人类服务部 基于hiv多进化枝的env的hiv疫苗
AU2004276559A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited HIV pharmaccines
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGENIC AND ITS APPLICATIONS
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP2243788A1 (en) * 2005-02-24 2010-10-27 Medical Research Council HIVCON: An HIV immunogen and uses thereof
AU2007256717B2 (en) * 2006-06-02 2013-06-20 International Aids Vaccine Initiative HIV-1 Clade A consensus sequences, antigens, and transgenes
WO2010096561A1 (en) * 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
JP2013507107A (ja) * 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2638060A2 (en) * 2010-11-10 2013-09-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
WO2014040025A2 (en) 2012-09-10 2014-03-13 International Aids Vaccine Initiative Immunogens of hiv-1 broadly neutralizing antibodies, methods of generation and uses thereof
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2015138698A1 (en) * 2014-03-12 2015-09-17 Temple University-Of The Commonwealth System Of Higher Education Dr6 receptor mediates the leukemia differentiation activity of angiocidin: a potent anti-tumor peptide
US10093720B2 (en) 2014-06-11 2018-10-09 International Aids Vaccine Initiative Broadly neutralizing antibody and uses thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9925258B2 (en) 2015-10-02 2018-03-27 International Aids Vaccine Initiative Replication-competent VSV-HIV Env vaccines
EP3426353A4 (en) 2016-03-09 2020-05-06 The University of Massachusetts USE OF MODIFIED HIV-1 TO GENERATE FULLY HUMAN ANTIBODIES
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020298552A1 (en) * 2019-07-02 2022-03-03 Seattle Project Corp. HIV antigens and MHC complexes
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2021185851A1 (en) 2020-03-17 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccine compositions for hiv prevention and treatment
JP2023521662A (ja) 2020-04-03 2023-05-25 グリットストーン バイオ インコーポレイテッド 感染症抗原及びワクチン
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784941A (en) * 1985-04-08 1988-11-15 Genetic Systems Corporation Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV
JP2869063B2 (ja) * 1985-04-08 1999-03-10 ジエネテイツク システムズ コ−ポレイシヨン ＬＡＶに対する抗体と免疫的に反応性であるｇａｇによりコードされたペプチドの発現及び使用
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5175098A (en) * 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to HIV
US5175097A (en) * 1985-08-07 1992-12-29 Genetic Systems Corporation Expression and diagnostic use of GAG-1 encoded peptides which are immunologically reactive with antibodies to HIV
US5134227A (en) * 1986-02-27 1992-07-28 Centocor, Inc. DNA encoding immunoreactive, chimeric HTLV-III GAG proteins
US4808536A (en) * 1986-02-27 1989-02-28 Centocor, Inc. Immunochemical method for detection of antibody against HTLV-III core protein based upon recombinant HTLV-III gag gene encoded protein
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
US5993819A (en) * 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
DE346022T1 (de) * 1988-06-10 1990-05-23 Medical Research Council, London Peptidfragmente von hiv.
US5817318A (en) * 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
US5210181A (en) * 1989-05-15 1993-05-11 Akzo N.V. T-lymphotropic retrovirus peptide
GB8918200D0 (en) * 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
CA2025634A1 (en) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
CA2084386C (en) * 1992-06-04 2001-02-20 Atsushi Saito Hiv antigen
JP3277045B2 (ja) * 1992-10-06 2002-04-22 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング Ｈｉｖ−グループのレトロウイルスおよびその使用
AU693098B2 (en) * 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
US6225045B1 (en) * 1996-05-13 2001-05-01 Ribotargets, Ltd. Assays for screening for inhibitors of HIV
CA2262432A1 (en) * 1996-08-09 1998-02-19 Viral Technologies, Inc. Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
WO1998043669A1 (en) * 1997-04-03 1998-10-08 Thomas Jefferson University Chimeric viral proteins
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
US6656471B1 (en) * 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1088889A1 (en) * 1999-10-01 2001-04-04 University Of Cambridge Recombinant double hybrid filamentous bacteriophage

Also Published As

Publication number Publication date
DE60043856D1 (de) 2010-04-01
JP2003518931A (ja) 2003-06-17
CA2392877A1 (en) 2001-07-05
PT1240186E (pt) 2010-03-25
CN1434831A (zh) 2003-08-06
AU2208901A (en) 2001-07-09
DK1240186T3 (da) 2010-05-31
WO2001047955A3 (en) 2002-05-10
CN1213068C (zh) 2005-08-03
US7993651B2 (en) 2011-08-09
HK1058048A1 (en) 2004-04-30
JP4805511B2 (ja) 2011-11-02
WO2001047955A2 (en) 2001-07-05
AU784679B2 (en) 2006-05-25
CA2392877C (en) 2011-11-15
ES2341429T3 (es) 2010-06-21
EP1240186B1 (en) 2010-02-17
EP1240186A2 (en) 2002-09-18
MXPA02006379A (es) 2004-06-21
CY1110917T1 (el) 2015-06-10
ATE457996T1 (de) 2010-03-15
US20030108562A1 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
ATE457996T1 (de) Verbesserungen in oder in bezug auf immunantworten gegen hiv
Reynolds et al. T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase.
Venable et al. Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein
DE68924162D1 (de) Stressproteine und verwendungen dafür.
Chang et al. Detection of antibodies to human T-cell lymphotropic virus-III (HTLV-III) with an immunoassay employing a recombinant Escherichia coli-derived viral antigenic peptide
DK177286D0 (da) Viruskappeprotein
EP1001032A3 (en) Recombinant retroviruses delivering vector constructs to target cells
AU6642390A (en) Methods and compositions for promoting immunopotentiation
PT1042363E (pt) Novos imunogenes anti-hiv (toxóides), processos de preparação e de aplicação para a prevenção e para o tratamento do sida
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
PL363071A1 (pl) Sposoby i kompozycje dla zmniejszenia replikacji HIV-1
WO1989002277A3 (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
Krohn et al. Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.
Kagnoff et al. Celiac sprue: correlation with murine T cell responses to wheat gliadin components.
BR0114046A (pt) Peptìdeos reguladores e auxiliares de hiv, antìgenos, composições de vacinas, kit de imunoensaio e um método para detectar anticorpos induzidos por hiv
DE68925660D1 (de) Peptidfragmente von HIV
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
Kurata et al. Immunodominant sites of human T cell lymphotropic virus type 1 envelope protein for murine helper T cells.
Talmadge et al. Identity between human interferon‐γ and “macrophage‐activating factor” produced by human T lymphocytes
Maillère et al. Role of thiols in the presentation of a snake toxin to murine T cells
KR880700820A (ko) 맥관인자(paf)
US6103239A (en) Modified HGP-30 heteroconjugates, compositions and methods of use
BR0210486A (pt) Proteìna, polipeptìdeo recombinante, sequência e vetor de ácido nucleico, célula em cultura, iniciador nucleotìdico, anticorpo purificado, composições imunogênica, de vacina e farmacêutica, processo de triagem de moléculas susceptìveis de inibir o crescimento de leishmania major, utilização de uma sonda de ácido nucleico, de um ou vários inibidores de proteìnas dissulfetos isomerases e de bacitracina ou de bacitracina de zinco, método de diagnóstico in vitro de uma infecção por um parasita responsável pela leishmaniose e kit diagnóstico para a realização do método
DK708488D0 (da) Faktor i praeparat

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O VALOR PAGO NO PEDIDO DE EXAME NAO CORRESPONDE AO VALOR REFERENTE AO NUMERO DE REIVINDICACOES SOLICITADAS.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A MANIFESTACAO FOI CONSIDERADA NAO SATISFATORIA, UMA VEZ QUE O VALOR PAGO PARA O EXAME DAS 45 REIVINDICACOES DO PEDIDO, NAO CORRESPONDE AOS VALORES DE RETRIBUICAO VIGENTES A EPOCA DO PEDIDO DE EXAME DO PRESENTE PEDIDO (REALIZADO EM 04/11/2003). PORTANTO, EM FACE DE TODO O EXPOSTO SE DESCONHECE A PETICAO DE PEDIDO DE EXAME, NO 061985 DE 04/11/2003, BASEANDO-SE NO ARTIGO 218, INCISO II DA LPI 9279/96.

B12F Other appeals [chapter 12.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: INTERNATIONAL AIDS VACCINE INITIATIVE (US) , UNIVE

Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110120541/RJ DE 24/11/2011.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2224 DE 20/08/2013.